Tungaraza Tongeji E
Partnerships in Care, Beverley House, 527-529 City Road, Birmingham B17 8LL, UK.
Ther Adv Psychopharmacol. 2016 Oct;6(5):335-342. doi: 10.1177/2045125316649534. Epub 2016 May 31.
It has been repeatedly shown that clozapine is more efficacious than other antipsychotics in the management of treatment-resistant schizophrenia. However, clozapine is associated with a number of side effects including weight gain. Antipsychotic-induced weight gain has been linked with a number of untoward events including psychological factors such as stigma and low self-esteem, and physical factors such as metabolic syndromes and untimely death. The mechanism underlying antipsychotic (including clozapine)-induced weight gain is not clearly understood, although it is said to involve several brain areas, several neurotransmitters, neuropeptides and genetic factors. To some individuals however, clozapine use is associated with significant weight loss (13.5-50% of body weight). The observed weight loss in these groups of patients has not been attributed to any underlying diagnosable physical disorders. There have been a handful cases published with this phenomenon, which seems to be contrary to what is expected when clozapine is prescribed. From the currently published cases three groups emerge - those who lost weight simply by taking clozapine, those who lost weight due to improved mental state, engaging in diet and increased exercise, and those for whom weight loss was a sign of a poor response to clozapine. A case of JX who has a diagnosis of schizoaffective disorder is presented. JX lost over 26% of her body weight when she was prescribed clozapine. A detailed review of other published cases is undertaken. The underlying mechanisms involving weight loss are discussed and the implications to clinicians are highlighted. Coordinated studies to examine these groups of patients may provide some insight, not only in the mechanism of clozapine-induced weight loss, but also in the better management of patients with treatment-resistant schizophrenia involving clozapine use.
反复研究表明,在治疗难治性精神分裂症方面,氯氮平比其他抗精神病药物更有效。然而,氯氮平会引发多种副作用,包括体重增加。抗精神病药物所致体重增加与许多不良事件相关,包括心理因素如耻辱感和自卑,以及身体因素如代谢综合征和过早死亡。尽管据说抗精神病药物(包括氯氮平)所致体重增加的机制涉及多个脑区、多种神经递质、神经肽和遗传因素,但目前尚不清楚其确切机制。然而,对一些个体而言,使用氯氮平会导致显著体重减轻(体重减轻13.5%至50%)。这些患者群体中观察到的体重减轻并非由任何可诊断的潜在身体疾病所致。已有少数关于这种现象的病例发表,这似乎与开具氯氮平时的预期情况相反。从目前已发表的病例中可分为三组——仅通过服用氯氮平体重减轻的患者、因精神状态改善、控制饮食和增加运动而体重减轻的患者,以及体重减轻表明对氯氮平反应不佳的患者。本文介绍了一例诊断为分裂情感性障碍的JX患者。JX在服用氯氮平后体重减轻超过26%。本文还对其他已发表病例进行了详细回顾。讨论了体重减轻的潜在机制,并强调了对临床医生的启示。对这些患者群体进行的协同研究可能不仅有助于深入了解氯氮平所致体重减轻的机制,还能更好地管理使用氯氮平的难治性精神分裂症患者。